Fuzuloparib

DRUG4 trials

Sponsors

Jiangsu Hengrui Pharmaceuticals Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Fujian Cancer Hospital, Qinglei Gao

Conditions

Metastatic Castration-Resistant Prostate CancerOvarian CancerOvarian DiseasesOvarian NeoplasmsSolid Tumor

Phase 1

A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects

CompletedNCT05440006

Jiangsu HengRui Medicine Co., Ltd.Solid Tumor

Start: 2022-07-03End: 2022-07-20Updated: 2022-09-08

Phase 2

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

RecruitingNCT05753826

Fujian Cancer HospitalOvarian Diseases, Ovarian Neoplasms

Start: 2023-08-01End: 2027-12-31Target: 37Updated: 2024-02-06

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Not yet recruitingNCT07355010

Qinglei GaoOvarian Cancer

Start: 2025-12-30End: 2030-12-30Target: 104Updated: 2026-01-21

Phase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingCTIS2023-509396-16-00

Jiangsu Hengrui Pharmaceuticals Co. Ltd.Metastatic Castration-Resistant Prostate Cancer

Start: 2021-11-08Target: 136Updated: 2025-12-05

Related Papers

Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer.

Journal of Clinical Oncology2024-06-011 citations